Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants
Latest Information Update: 11 Jul 2025
At a glance
- Drugs GV 101 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Graviton
Most Recent Events
- 03 Jul 2025 Status changed from not yet recruiting to recruiting.
- 27 May 2025 New trial record